EUVIMEDEUVIMED entdecken
Open Access

Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice

Yuanqing Lu, Regina Oshins, Nesmine R Maptue, Qingyang Shen, Chalermchai Khemtong iD, Kenneth Cusi iD, Mark Brantly iD, Nazli Khodayari iD

American Journal of Physiology-Gastrointestinal and Liver Physiology · 2025

DOI: 10.1152/ajpgi.00272.2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, 2025. Verfasst von Yuanqing Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Florida, Gainesville, Florida, United States. Hauptthemen laut MEDLINE: Pioglitazone, Autophagy, AMP-Activated Protein Kinases, alpha 1-Antitrypsin Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, Alpha-1 Foundation (A1F), HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

α-1 Antitrypsin deficiency (AATD)-mediated liver disease lacks therapies that reduce hepatic ZAAT accumulation and liver manifestations. We demonstrate that pioglitazone activates AMPK and induces autophagy, leading to decreased ZAAT and improved proteostasis in Pi*Z mouse livers and human hepatocyte models. As an FDA-approved drug with metabolic benefits, pioglitazone holds promise for repurposing in AATD-related liver disease. These findings offer a mechanistic rationale for targeting autophagy to alleviate hepatic injury in protein misfolding disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PioglitazoneAutophagyAMP-Activated Protein Kinasesalpha 1-Antitrypsin Deficiencyalpha 1-AntitrypsinLiverAnimalsMiceHumansHepatocytesMice, TransgenicMaleSignal Transduction

Stichwörter der Autor:innen

autophagypioglitazoneα-1 antitrypsin deficiency

Substanzen

PioglitazoneAMP-Activated Protein Kinasesalpha 1-Antitrypsin

Autor:innen und Institutionen

  • Department of Neurosurgery, University of Florida, Gainesville, Florida, United States.
  • Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, University of Florida, Gainesville, Florida, United States.
  • Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Florida, Gainesville, Florida, United States.
  • Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, United States.

ORCID-Profile: Chalermchai Khemtong, Kenneth Cusi, Mark Brantly, Nazli Khodayari

Förderung

  • NIBIB NIH HHS
  • Alpha-1 Foundation (A1F)
  • HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Zitieren

APA

Lu, Y., Oshins, R., Maptue, N. R., Shen, Q., Khemtong, C., Cusi, K., Brantly, M., & Khodayari, N. (2025). Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00272.2025

Vancouver

Lu Y, Oshins R, Maptue NR, Shen Q, Khemtong C, Cusi K, et al. Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2025. doi:10.1152/ajpgi.00272.2025

BibTeX
@article{Lu2025,
  author = {Lu, Yuanqing and Oshins, Regina and Maptue, Nesmine R and Shen, Qingyang and Khemtong, Chalermchai and Cusi, Kenneth and Brantly, Mark and Khodayari, Nazli},
  title = {Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice},
  journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
  year = {2025},
  doi = {10.1152/ajpgi.00272.2025}
}
Kostenlos starten →